The 'next move' for PO3 is clear - they are keen to establish for once and for all that FRG can kill airborne COVID.
The frustrating aspect of this is that this should have been done months ago. Sure - the outcome is almost a given - but until they can show it does what everyone thinks and hopes it does - we wait.
And while we wait....well - things don't exactly look that good from a competitor perspective. While Somnio burn through $$$ doing whatever it is they are doing (as shareholders certainly wouldn't know) - there has been activity in this space that may make a few holders feel a bit anxious.
Here's a snippet from an article published in the British Dental Journal - which, as part of the Nature group, is as credentialed as one can expect any publication to be.

While FRG may be better tech - and there may be arguments about '1st pass' effects etc - but what we see is...
- A commercialised solution established within the healthcare sector (imagine if this was a PO3 announcement three months ago!)
- Collaboration with Oxford university (great PR if nothing else...)
- Evaluated and approved by a Swiss 3rd party
- Successful trials in Chinese hospitals (don't get me started on the TB trial....)
Frustrating to say the least. As long as competitors gain a foothold - the ability for PO3 to break into this space becomes increasingly challenging.
In terms of full disclosure - I've been out of PO3 for a while now. But have watched very closely - while I lost complete faith in the board and had given up on giving them "one more quarter" - there does seem to be some movement in the right direction. New hires. More news. And a shift away from Michigan and back to Melbourne - from which it looks like there is motivation to finally commercialise this damn tech.
Good luck to all.
Here's the full article...
